USPTO serial 88166343
HELIXMITH
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Nov 12, 2019
- Examiner
- MAI, TINA HSIN
- Law office
- PUBLICATION AND ISSUE SECTION
What this means
Status 705 means a Madrid-based U.S. registration has accepted Section 71 maintenance and Section 15 incontestability. The U.S. extension is active with strengthened rights. Track next renewal deadlines in TSDR and WIPO records.
Need help with HELIXMITH?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Connie L. Ellerbach
Connie L. Ellerbach Fenwick & West LLP801 California StreetMountain View, CA 94041United StatesGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | [ reagents for use in veterinary genetic testing for medical use; chemical preparations for pharmaceutical purposes, namely, for treating neurological disease, muscular disease, ischemic disease, renal disease, cancer; chemical preparations for use in DNA analysis for medical use; drugs for medical purposes, namely, for treating neurological disease, muscular disease, ischemic disease, renal disease, cancer; reagents for use in medical genetic testing for medical use; pharmaceutical drugs, namely, for treating neurological disease, muscular disease, ischemic disease, renal disease, cancer; medicines for human purposes, namely, for treating neurological disease, muscular disease, ischemic disease, renal disease, cancer; pharmaceutical preparations for diagnosis; pharmaceutical preparations for the treatment of immune system related diseases and disorders; ethical medicinal preparations, namely, for treating neurological disease, muscular disease, ischemic disease, renal disease, cancer; therapeutic drugs and agents, namely, for treating neurological disease, muscular disease, ischemic disease, renal disease, cancer; biological preparations, namely, for treating neurological disease, muscular disease, ischemic disease, renal disease, cancer; crude medicines, namely, for treating neurological disease, muscular disease, ischemic disease, renal disease, cancer; biological preparations for medical use in medical and clinical gene therapy and cell therapy; pharmaceutical preparations, namely, for treating neurological disease, muscular disease, ischemic disease, renal disease, cancer; biological preparations for medical use, namely, for treating neurological disease, muscular disease, ischemic disease, renal disease, cancer ] | SECTION 8 - CANCELLED | — |
| 035 | [ Retail store services featuring reagents for use in veterinary genetic testing; retail store services featuring chemical preparations for pharmaceutical purposes; retail store services featuring chemical preparations for use in DNA analysis for medical use; retail store services featuring drugs for medical purposes; retail store services featuring reagents for use in medical genetic testing; retail store services featuring pharmaceutical preparations for diagnosis; retail store services featuring pharmaceutical preparations for the treatment of immune system related diseases and disorders; retail store services featuring ethical medicinal preparations; retail store services featuring therapeutic drugs and agents, retail store services featuring biological preparations for medical use ] | SECTION 8 - CANCELLED | — |
| 042 | Research and development of vaccines and medicines; [ providing information relating to scientific analysis of the genetic information via online networks; ] scientific research in the fields of biomedicine; [ biological information analysis, namely, genetic testing for medical research purposes; biological information analysis, namely, genetic testing for scientific research purposes; research and testing services in the fields of bacteriology and virology; ] drug discovery services; research and development in the pharmaceutical and biotechnology fields; providing medical and scientific research information in the field of pharmaceuticals and clinical trials; consultancy relating to the pharmaceutical research and development; pharmaceutical research and development; [ pharmaceutical research services; laboratory research in the field of gene expression; gene analysis for research; ] consultancy in analysis of biology sequence processing for medical research purposes; consultancy in analysis of genomics for medical research purposes; scientific research in the fields of medicine/health and pharmacology; analysis of human serum for medical research [ ; analysis of human tissues for medical research; blood analysis services ] | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by ViroMed Co., Ltd.
- Other trademarks owned by Helixmith Co., Ltd
- Other trademarks owned by ViroMed Co., Ltd.
- Other trademarks in Class 005
- Other trademarks in Class 035
- Other trademarks in Class 042
- Similar marks named HELIXMITH
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Jul 28, 2026 | NA85 | NOTICE OF ACCEPTANCE OF SEC. 8 & 15 - E-MAILED | — |
| Jul 28, 2026 | C15P | REGISTERED - PARTIAL SEC. 8 (6-YR) ACCEPTED & SEC. 15 ACK. | — |
| Jul 27, 2026 | APRE | CASE ASSIGNED TO POST REGISTRATION PARALEGAL | — |
| Apr 24, 2026 | E815 | TEAS SECTION 8 & 15 RECEIVED | — |
| Nov 12, 2024 | REM1 | COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED | — |
| Aug 25, 2020 | COC. | CORRECTION UNDER SECTION 7 - PROCESSED | — |
| Aug 10, 2020 | EROP | TEAS RESPONSE TO OFFICE ACTION-POST REG RECEIVED | — |
| Feb 19, 2020 | PRAM | POST REGISTRATION ACTION MAILED - SEC. 7 | — |
| Feb 18, 2020 | APRE | CASE ASSIGNED TO POST REGISTRATION PARALEGAL | — |
| Feb 18, 2020 | XXXX | POST REGISTRATION ACTION CORRECTION | — |
| Feb 18, 2020 | WDRL | OTQR WITHDRAWAL FROM PUBLICATION | — |
| Jan 21, 2020 | COC. | CORRECTION UNDER SECTION 7 - PROCESSED | — |
| Jan 21, 2020 | APRE | CASE ASSIGNED TO POST REGISTRATION PARALEGAL | — |
| Dec 3, 2019 | ES7R | TEAS SECTION 7 REQUEST RECEIVED | — |
| Nov 12, 2019 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Oct 6, 2019 | ETOP | EXTENSION OF TIME TO OPPOSE PROCESS - TERMINATED | — |
| Jun 19, 2019 | ASCK | ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY | — |
| Jun 11, 2019 | ETOF | EXTENSION OF TIME TO OPPOSE RECEIVED | — |
| May 28, 2019 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| May 28, 2019 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| May 8, 2019 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Apr 22, 2019 | FIXD | ELECTRONIC RECORD REVIEW COMPLETE | — |
| Apr 12, 2019 | ERRR | ON HOLD - ELECTRONIC RECORD REVIEW REQUIRED | — |
| Apr 3, 2019 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Apr 3, 2019 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Apr 3, 2019 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| Apr 3, 2019 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| Apr 3, 2019 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Mar 30, 2019 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Mar 29, 2019 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Mar 29, 2019 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Mar 22, 2019 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Mar 22, 2019 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Mar 22, 2019 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Mar 13, 2019 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Mar 13, 2019 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Mar 8, 2019 | ALIE | ASSIGNED TO LIE | — |
| Mar 5, 2019 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Jan 5, 2019 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jan 5, 2019 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jan 5, 2019 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jan 3, 2019 | DOCK | ASSIGNED TO EXAMINER | — |
| Nov 5, 2018 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Oct 26, 2018 | NWAP | NEW APPLICATION ENTERED | — |